American Society of Hirudotherapy

Applications of leech therapy in medicine: a systematic review

Hosseini M, Jadidi A, Derakhshan Barjoei MM, Salehi M (2024) · Frontiers in Medicine · n=12

Review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Study record: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
GRADE LowSystematic reviewLeech therapy in other conditions

Study Profile

Design
PRISMA-compliant systematic review of clinical trials of leech therapy across all indications (PubMed/Scopus/Web of Science through April 2023); Arak University of Medical Sciences and Shahid Beheshti University, Iran
Pooled sample (n; included studies may overlap)
12
Scope
Whole-leech (Hirudo medicinalis and regional species) therapy across heterogeneous indications including knee OA, varicose veins, infertility, diabetes/lipid metabolism, hypertension
Main result
12 trials met inclusion criteria; review concludes leech therapy has 'successful outcomes' across hormonal/metabolic complications, cardiovascular conditions, and inflammatory diseases; complications acknowledged but described as manageable with preventive measures; authors call for higher-quality RCTs

Key Findings

  • 12 clinical trials of leech therapy across all indications (through April 2023)
  • Authors note efficacy signals in metabolic, cardiovascular, and inflammatory conditions
  • Cochrane bias analysis identified considerable heterogeneity in methods and risk of bias
  • Complications acknowledged: localized pain, mild bleeding, occasional infection
  • Authors call for larger high-quality RCTs across indications

Limitations

  • Wide indication scope prevents condition-specific GRADE pooling
  • Mixed inclusion of low-quality trials weakens overall confidence
  • Limited to English-language databases; missed substantial Russian, Turkish, Persian, Hindi/Sanskrit-language hirudotherapy literature
  • Cochrane bias tool used without explicit risk-of-bias table per indication
  • 12 trials is a small base for multi-indication conclusions

Clinical Implications

Hosseini 2024 is a useful contemporary snapshot of the leech-therapy clinical literature but should not be used in isolation to support specific indication claims. For ASH clinicians and researchers, the review reinforces (1) the persistent quality gap between hirudotherapy and pharmacologic comparator literatures, (2) the need for trial-quality standardization (CONSORT-compliant reporting), and (3) the value of indication-specific systematic reviews (e.g., Lauche 2014 for knee OA, Rajaram 2024 for breast surgery) over broad multi-indication reviews.

Related studies

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.